Elvira Crescenzi

Dr. Elvira Crescenzi

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Adriano RossiAdriano Rossi
Adriano Rossi
DSDeborah A Sawatzky
Deborah A Sawatzky
AWAnnemieke Walker
Annemieke Walker
CWCarol Ward
Carol Ward
TSTara A Sheldrake
Tara A Sheldrake
CHChristopher Haslett
Christopher Haslett

16 September 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AIAlessio Iannetti
Alessio Iannetti
FPFrancesco Maria Pacifico
Francesco Maria Pacifico
RARenato Acquaviva
Renato Acquaviva
ALAlfonso Lavorgna
Alfonso Lavorgna
ECElvira Crescenzi
Elvira Crescenzi
ALAntonio Leonardi
Antonio Leonardi
NF-κB is constitutively activated in primary human thyroid tumors, particularly in those of anaplastic type. The inhibition of NF-κB activity in the human anaplastic thyroid carcinoma cell line, FRO, leads to an increased susceptibility to chemotherapeutic drug-induced apoptosis and to the blockage of their ability to form tumors in nude mice. To identify NF-κB target genes involved in thyroid cancer, we analyzed the secretome of conditioned media from parental and NF-κB-null FRO cells. Proteomic analysis revealed that the neutrophil gelatinase-associated lipocalin (NGAL), a protein involved in inflammatory and immune responses, is secreted by FRO cells whereas its expression is strongly reduced in the NF-κB-null FRO cells. NGAL is highly expressed in human thyroid carcinomas, and knocking down its expression blocks the ability of FRO cells to grow in soft agar and form tumors in nude mice. These effects are reverted by the addition of either recombinant NGAL or FRO conditioned medium. In addition, we show that the prosurvival activity of NGAL is mediated by its ability to bind and transport iron inside the cells. Our data suggest that NF-κB contributes to thyroid tumor cell survival by controlling iron uptake via NGAL.

1 March 2010 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
FPFrancesco Maria Pacifico
Francesco Maria Pacifico
ECElvira Crescenzi
Elvira Crescenzi
SMStefano Mellone
Stefano Mellone
AIAlessio Iannetti
Alessio Iannetti
NPNunzio Porrino
Nunzio Porrino
ALAntonio Leonardi
Antonio Leonardi
Context: Micro-RNAs (miRNAs) have been recently involved in the modulation of several biological activities including cancer. Many human tumors show deregulated expression of miRNAs targeting oncogenes and/or tumor suppressors, thus identifying miRNAs as new molecular targets for cancer therapy. Objectives: Nuclear factor (NF)-κB is strongly activated in human anaplastic thyroid carcinomas (ATCs). Because the regulation of miRNA expression is under control of RNA polymerase II-dependent transcription factors, we stably inactivated NF-κB in the ATC-derived FRO cell line and analyzed its miRNA profile in comparison with the parental counterpart by using a miRNA chip microarray. Results: The analysis revealed that a number of miRNAs were differentially expressed in the two cell lines. Among others, the miR-146a showed a strong down-regulation that was confirmed by quantitative real time RT-PCR. The expression of miR-146a was almost undetectable in mouse embryonic fibroblasts isolated from the RelA knockout mice and was restored after reexpression of RelA, thus indicating that miR-146a transcription was controlled by NF-κB. The inhibition of miR-146a expression in FRO cells decreased their oncogenic potential and increased the susceptibility to chemotherapeutic drug-induced apoptosis. No difference was found in the growth rate between untransfected and miR-146a-null FRO cells. Importantly, the miR-146a resulted in overexpression of human ATC specimens compared with the normal thyroid tissue. Conclusions: Our results show that NF-κB contributes to anaplastic thyroid cancer up-regulating the expression of miR-146a.

1 December 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
FPFrancesco Maria Pacifico
Francesco Maria Pacifico
CMClaudio Mauro
Claudio Mauro
CBCiro Barone
Ciro Barone
ECElvira Crescenzi
Elvira Crescenzi
SMStefano Mellone
Stefano Mellone
ALAntonio Leonardi
Antonio Leonardi
Thyroid cancer includes three types of carcinomas classified as differentiated thyroid carcinomas (DTC), medullary thyroid carcinomas, and undifferentiated carcinomas (UTC). DTC and medullary thyroid carcinomas generally have a good prognosis, but UTC are usually fatal. Consequently, there is a need for new effective therapeutic modalities to improve the survival of UTC patients. Here we show that NF-κB is activated in human thyroid neoplasms, particularly in undifferentiated carcinomas. Thyroid cell lines, reproducing in vitro the different thyroid neoplasias, also show basal NF-κB activity and resistance to drug-induced apoptosis, which correlates with the level of NF-κB activation. Activation of NF-κB in the DTC cell line NPA renders these cells resistant to drug-induced apoptosis. Stable expression of a super-repressor form of IκBα (IκBαM) in the UTC cell line FRO results in enhanced sensitivity to drug-induced apoptosis, to the loss of the ability of these cells to form colonies in soft agar, and to induce tumor growth in nude mice. In addition, we show that FRO cells display a very low JNK activity that is restored in FRO-IκBαM clones. Moreover, inhibition of JNK activity renders FRO-IκBαM clones resistant to apoptosis induced by chemotherapeutic agents. Our results indicate that NF-κB plays a pivotal role in thyroid carcinogenesis, being required for tumor growth and for resistance to drug-induced apoptosis, the latter function very likely through the inhibition of JNK activity. Furthermore, the strong constitutive NF-κB activity in human anaplastic thyroid carcinomas, besides representing a novel diagnostic tool, makes NF-κB a target for the development of novel therapeutic strategies.

1 May 2004 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
ECElvira Crescenzi
Elvira Crescenzi
LVLinda Varriale
Linda Varriale
MIMariangela Iovino
Mariangela Iovino
ACAngela Chiaviello
Angela Chiaviello
BVBianca Maria Veneziani
Bianca Maria Veneziani
GPGiuseppe Palumbo
Giuseppe Palumbo
Objective: We investigated the effects of photodynamic therapy (PDT) combined with low-dose chemotherapy on breast cancer cells. Photodynamic treatment was administered by irradiating indocyanine green-preloaded MCF-7 cells with an IR diode laser source at 805 nm; cisplatin was used for chemotherapy. Methods: The dose-response phenomena associated with the two treatments administered individually and together were evaluated with the following tests: trypan blue dye exclusion, 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assay, clonogenic survival, thymidine and methionine incorporation, and insulin-dependent and insulin-independent glucose transport. Results: Viability and metabolic data demonstrated mutual reinforcement of therapeutic efficacy. However, isobolographic analysis of quantal and variable data indicated that reinforcement was additive according to trypan blue data and synergistic according to MTT data. To investigate the molecular mechanisms underlying alterations in cell proliferation and apoptosis, we evaluated (by Western blotting) the expression of proteins Bcl-2, Bax, Bcl-XL, p21, p53, and poly(ADP-ribose) polymerase. Photodynamic treatment caused transient selective destruction of Bcl-2 and up-regulation of Bax. It also induced apoptosis in a limited fraction of cells (10–12%). Flow cytometry data showed that PDT killed mostly G1-phase cells, whereas cisplatin killed mostly S-phase cells. This disjointed phase-related effect may account for the favorable effects exerted by combined treatment. Conclusions: Our findings imply that low doses of cytostatic drugs may be as effective or even more effective than currently used doses if appropriately combined with PDT.

1 October 1996 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
GPGiuseppe Palumbo
Giuseppe Palumbo
MCMatilde Caruso
Matilde Caruso
ECElvira Crescenzi
Elvira Crescenzi
Mario Felice TecceMario Felice Tecce
Mario Felice Tecce
GRGiuseppe Roberti
Giuseppe Roberti
ACAlberto Colasanti
Alberto Colasanti